Core Viewpoint - The article provides an overview of recent IPO activities in Hong Kong, the US, and A-shares, highlighting key companies and their market positions. Group 1: Changfeng Pharmaceutical - Changfeng Pharmaceutical officially listed on the Hong Kong Stock Exchange on October 8, 2025, under the stock code "2652" [3] - The global offering consisted of 41.198 million shares, with the Hong Kong public offering being oversubscribed by 6,697.80 times, marking the second-highest oversubscription since the revised pricing mechanism was implemented [3] - The company specializes in inhalation formulations and has a comprehensive product portfolio addressing significant clinical needs in respiratory diseases, including asthma and COPD [4] - The CEO emphasized the advantages of inhalation therapies and the company's commitment to innovation in this field, aiming to create long-term value for shareholders [4] Group 2: Yunji Technology - Yunji Technology plans to list on the Hong Kong Stock Exchange on October 16, 2025, with the stock code "2670" [6] - The company holds a leading position in China's robot service AI market, with a 6.3% market share and a 13.9% share in the hotel service sector [6] - Its products are used in over 34,000 hotels globally, and it has established partnerships with major hotel groups [6] - Financially, Yunji Technology's revenue grew from 161 million yuan in 2022 to 245 million yuan in 2024, with a compound annual growth rate of 23.2% [8] Group 3: Qichacha Technology - Qichacha's IPO application was accepted on October 10, 2025, aiming to list on the Shanghai Stock Exchange [10] - The company provides comprehensive business data services, helping users understand various commercial entities' credit and risk [10] - As of June 2023, Qichacha had over 150 million registered users and ranked second in market share among business data service providers in China [11] - The company reported revenues of 518 million yuan in 2022, with a net profit margin exceeding 45% [12] Group 4: InxMed Limited - InxMed Limited submitted its prospectus for listing on the Hong Kong Stock Exchange, focusing on improving cancer treatment paradigms [14] - The company is the only one in China with a selective FAK inhibitor in late-stage clinical trials, with a product pipeline that includes ifebemtinib [14][15] - Ifebemtinib is positioned to be a leading treatment option for various cancers, with regulatory recognition for its clinical potential [15] - InxMed has secured over 929 million yuan in investments from notable institutions, with a pre-IPO valuation of 306 million USD [16][17]

Core Viewpoint - Qichacha Technology Co., Ltd. has received approval for its IPO application, aiming to raise over 1.5 billion yuan, focusing on enhancing its commercial big data services for both C-end and B-end users [1][3]. Group 1: Company Overview - Founded in 2014, Qichacha specializes in providing accurate and efficient commercial data services to help users understand credit, risks, opportunities, and information related to various business entities [1]. - The company launched its first paid product, Qichacha VIP membership, in 2016, followed by other premium offerings tailored to both C-end and B-end users [1]. Group 2: Market Position - According to the "China Commercial Big Data Service Industry Blue Book" and QuestMobile data, Qichacha ranks second in market share among domestic commercial big data service providers and first in mobile app downloads [2]. - As of June 2023, Qichacha has over 150 million registered users, with a steady increase in paid users from 906,200 in 2022 to 1,048,000 in the first half of 2024 [2]. Group 3: Financial Performance - Qichacha's revenue for 2022, 2023, and projected for 2024 are 518 million yuan, 618 million yuan, and 708 million yuan, respectively, reflecting a compound annual growth rate of 16.89% [3]. - The company's net profit for the same years is reported as 190 million yuan, 256 million yuan, and 317 million yuan, with a net profit margin exceeding 45% [3]. Group 4: Future Plans - The funds raised from the IPO will be primarily allocated to upgrading C-end and B-end commercial big data products, enhancing a multi-dimensional database, and developing artificial intelligence capabilities in commercial big data [3]. - Qichacha's chairman highlighted the potential for growth in revenue, data assets, and management efficiency, aiming to establish a competitive edge in the international market [4].